Search Results - "Kister, I"

Treatment of MOG antibody associated disorders: results of an international survey by Whittam, D. H., Karthikeayan, V., Gibbons, E., Kneen, R., Chandratre, S., Ciccarelli, O., Hacohen, Y., de Seze, J., Deiva, K., Hintzen, R. Q., Wildemann, B., Jarius, S., Kleiter, I., Rostasy, K., Huppke, P., Hemmer, B., Paul, F., Aktas, O., Pröbstel, A. K., Arrambide, G., Tintore, M., Amato, M. P., Nosadini, M., Mancardi, M. M., Capobianco, M., Illes, Z., Siva, A., Altintas, A., Akman-Demir, G., Pandit, L., Apiwattankul, M., Hor, J. Y., Viswanathan, S., Qiu, W., Kim, H. J., Nakashima, I., Fujihara, K., Ramanathan, S., Dale, R. C., Boggild, M., Broadley, S., Lana-Peixoto, M. A., Sato, D. K., Tenembaum, S., Cabre, P., Wingerchuk, D. M., Weinshenker, B. G., Greenberg, B., Matiello, M., Klawiter, E. C., Bennett, J. L., Wallach, A. I., Kister, I., Banwell, B. L., Traboulsee, A., Pohl, D., Palace, J., Leite, M. I., Levy, M., Marignier, R., Solomon, T., Lim, M., Huda, S., Jacob, A.

“…Introduction While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed…”
Get full text

Extended interval dosing of natalizumab in multiple sclerosis by Zhovtis Ryerson, L, Frohman, T C, Foley, J, Kister, I, Weinstock-Guttman, B, Tornatore, C, Pandey, K, Donnelly, S, Pawate, S, Bomprezzi, R, Smith, D, Kolb, C, Qureshi, S, Okuda, D, Kalina, J, Rimler, Z, Green, R, Monson, N, Hoyt, T, Bradshaw, M, Fallon, J, Chamot, E, Bucello, M, Beh, S, Cutter, G, Major, E, Herbert, J, Frohman, E M

“…BackgroundNatalizumab (NTZ), a monoclonal antibody to human α4β1/β7 integrin, is an effective therapy for multiple sclerosis (MS), albeit associated with…”
Get full text

Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI by Chawla, S, Kister, I, Wuerfel, J, Brisset, J-C, Liu, S, Sinnecker, T, Dusek, P, Haacke, E M, Paul, F, Ge, Y

“…Characterization of iron deposition associated with demyelinating lesions of multiple sclerosis and neuromyelitis optica has not been well studied. Our aim was…”
Get full text

Conventional brain MRI in neuromyelitis optica by Cabrera-Gomez, J. A., Kister, I.

“…Background and purpose:  Numerous case series have demonstrated that lesions on brain MRI are common in neuromyelitis optica (NMO), but there has not been an…”
Get full text

Development and validation of a simple and practical method for differentiating MS from other neuroinflammatory disorders based on lesion distribution on brain MRI by Patel, J., Pires, A., Derman, A., Fatterpekar, G., Charlson, R.E., Oh, C., Kister, I.

“…•MS, NMOSD, and MOGAD are different diseases that may look similar on brain MRI.•We identified 3 lesion locations on brain MRI that differentiate MS from…”
Get full text

SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple Domains by Green, R., Kalina, J., Ford, R., Pandey, K., Kister, I.

“…The objective of this study was to describe SymptoMScreen, an in-house developed tool for rapid assessment of MS symptom severity in routine clinical practice,…”
Get full text

Natalizumab-induced hepatic injury: A case report and review of literature by Antezana, A, Sigal, S, Herbert, J, Kister, I

“…Abstract Natalizumab is an α4-integrin monoclonal antibody used for treatment of relapsing multiple sclerosis (MS). At least and nearly 30 cases of liver…”
Get full text

SPECIFIC MRI FINDINGS HELP DISTINGUISH ACUTE TRANSVERSE MYELITIS OF NEUROMYELITIS OPTICA FROM SPINAL CORD INFARCTION by Kister, I, Johnson, E, Raz, E, Babb, J, Loh, J, Shepherd, TM

“…Abstract Background There is substantial overlap between MRI of acute spinal cord lesions from neuromyelitis optica (NMO) and spinal cord infarct (SCI) in…”
Get full text

Rapid disease course in African Americans with multiple sclerosis by KISTER, I, CHAMOT, E, JUBELT, B, KRUPP, L, LENIHAN, M, LUBLIN, F, MIHAI, C, MILLER, A, MUNSCHAUER, F. E, PEREL, A. B, TETER, B. E, WEINSTOCK-GUTTMAN, B, BACON, J. H, ZIVADINOV, R, HERBERT, J, NIEWCZYK, P. M, DE GUZMAN, R. A, APATOFF, B, COYLE, P, GOODMAN, A. D, GOTTESMAN, M, GRANGER, C

“…To investigate utility of a Multiple Sclerosis Severity Scale (MSSS)-based classification system for comparing African American (AA) and white American (WA)…”
Get full text

CSF plasmablasts differentiate MS from other neurologic disorders by Kister, I., Lotan, I., Wallach, A., Bacon, T., Cutter, G., Arbini, A.

“…Multiparametric flow cytometry (FC) of CSF allows one to easily estimate the percentage of lymphocyte subpopulations in CSF. We hypothesized that an increased…”
Get full text

Special Considerations for Rapid Drug Desensitization With Natalizumab by Sutaria, M, Miro, K, Mathew, A, Kister, I, Feigenbaum, B.A

“…[...]one must open another vial of natalizumab, costing approximately $3,000, or the patient will only receive approximately 90% of the typical intended dose…”
Get full text

Occurrence of CNS demyelinating disease in patients with myasthenia gravis by Weinshenker, Brian G, Jacob, Anu

Get full text

Occurrence of CNS demyelinating disease in patients with myasthenia gravis by Kister, I, Herbert, J, Swerdlow, M L, Bergamaschi, R, Piccolo, G, Oger, J

Get full text

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study by He, Anna, Merkel, Bernd, Brown, James William L, Zhovits Ryerson, Lana, Kister, Ilya, Malpas, Charles B, Sharmin, Sifat, Horakova, Dana, Kubala Havrdova, Eva, Spelman, Tim, Izquierdo, Guillermo, Eichau, Sara, Trojano, Maria, Lugaresi, Alessandra, Hupperts, Raymond, Sola, Patrizia, Ferraro, Diana, Lycke, Jan, Grand'Maison, Francois, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Larochelle, Catherine, Svenningsson, Anders, Petersen, Thor, Grammond, Pierre, Granella, Franco, Van Pesch, Vincent, Bergamaschi, Roberto, McGuigan, Christopher, Coles, Alasdair, Hillert, Jan, Piehl, Fredrik, Butzkueven, Helmut, Kalincik, Tomas

“…High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised…”
Get full text

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study by Kister, Ilya, Spelman, Tim, Alroughani, Raed, Lechner-Scott, Jeannette, Duquette, Pierre, Grand'Maison, Francois, Slee, Mark, Lugaresi, Alessandra, Barnett, Michael, Grammond, Pierre, Iuliano, Gerardo, Hupperts, Raymond, Pucci, Eugenio, Trojano, Maria, Butzkueven, Helmut

“…BackgroundDiscontinuation of injectable disease-modifying therapy (DMT) for multiple sclerosis (MS) after a long period of relapse freedom is frequently…”
Get full text

Neurologic manifestations of localized scleroderma : A case report and literature review by KISTER, Ilya, INGLESE, Matilde, LAXER, Ronald M, HERBERT, Joseph

“…We describe a young woman with localized scleroderma, seizures, numerous persistently enhancing white matter lesions on brain MRI, and oligoclonal bands in the…”
Get full text

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis by He, Anna, Spelman, Tim, Jokubaitis, Vilija, Havrdova, Eva, Horakova, Dana, Trojano, Maria, Lugaresi, Alessandra, Izquierdo, Guillermo, Grammond, Pierre, Duquette, Pierre, Girard, Marc, Pucci, Eugenio, Iuliano, Gerardo, Alroughani, Raed, Oreja-Guevara, Celia, Fernandez-Bolaños, Ricardo, Grand'Maison, Francois, Sola, Patrizia, Spitaleri, Daniele, Granella, Franco, Terzi, Murat, Lechner-Scott, Jeannette, Van Pesch, Vincent, Hupperts, Raymond, Sánchez-Menoyo, José Luis, Hodgkinson, Suzanne, Rozsa, Csilla, Verheul, Freek, Butzkueven, Helmut, Kalincik, Tomas

“…After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the…”
Get more information

Ultra-High-Field MR Imaging of Brain Lesions of Neuromyelitis Optica Spectrum Disorders (NMOsd): Absence of Central Venule within Lesions May Help Differentiate NMOsd from Multiple Sclerosis (P03.045) by Kister, I., Herbert, J., Ge, Y.

“…Abstract only…”
Get full text

Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS by Zivadinov, R, Bergsland, N, Korn, J R, Dwyer, M G, Khan, N, Medin, J, Price, J C, Weinstock-Guttman, B, Silva, D

“…Feasibility of brain atrophy measurement in patients with MS in clinical routine, without prior standardization of the MRI protocol, is unknown. Our aim was to…”
Get full text

Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry by Kenney, Rachel, Liu, Mengling, Patil, Sachi, Alroughani, Raed, Ampapa, Radek, Bergamaschi, Roberto, Boz, Cavit, Butzkueven, Helmut, Gomez, Jose Cabrera, Cartechini, Elisabetta, Madueño, Sara Eichau, Ferraro, Diana, Grand-Maison, Francois, Granella, Franco, Horakova, Dana, Izquierdo Ayuso, Guillermo, Kalincik, Tomas, Lizrova Preiningerova, Jana, Lugaresi, Alessandra, Onofrj, Marco, Ozakbas, Serkan, Patti, Francesco, Sola, Patrizia, Soysal, Aysun, Spitaleri, Daniele Litterio A., Terzi, Murat, Turkoglu, Recai, van Pesch, Vincent, Saidha, Shiv, Thorpe, Lorna E., Galetta, Steven L., Balcer, Laura J., Kister, Ilya, Spelman, Tim

“…Short-term outcomes of optic neuritis (ON) have been well characterized. Limited data exists on longer-term visual outcomes in patients who present with ON…”
Get full text